New Intravesical Delivery Systems and TAR-200 in NMIBC

Author(s):

Chad A. Reichard, MD ,Karim Chamie, MD, MSHS

Experts review different treatment delivery options available for the management of non–muscle-invasive bladder cancer (NMIBC), discuss the exciting developments in NMIBC with several delivery systems and agents under investigation, and provide information about TAR-200, a targeted release system utilizing continuous intravesical release of gemcitabine, including how TAR-200 is installed within the bladder.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

EP: 2.Cystectomy in NMIBC

Now Viewing

EP: 3.New Intravesical Delivery Systems and TAR-200 in NMIBC

EP: 4.TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP: 5.TAR-200 Clinical Development Program in NMIBC

EP: 6.Other Investigational Drug Delivery Systems in NMIBC

EP: 7.Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP: 8.FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP: 9.Use and Sequencing of Novel Treatments in NMIBC

EP: 10.Communication of Treatment Options for High-Risk NMIBC

EP: 11.Checkpoint Inhibitors for Treatment of NMIBC

EP: 12.Unmet Needs in NMIBC

EP: 13.Operationalizing TAR-200 and Other Delivery Systems in Practice

Video content above is prompted by the following:

Please review different treatment delivery options available for management of NMIBC.
It is an exciting time for NMIBC, as several delivery systems and agents are currently under investigation for treatment of NMIBC.
To start with, please share information about TAR-200, a targeted release system that utilizes continuous intravesical release of gemcitabine.
Describe how TAR-200 is installed within the bladder.